Matt Abernethy - 12 Jun 2026 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Reporting relationship: Director
Issuer ticker: FATE
Reported as of: 12 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 16:07:22 UTC
Prior SEC filing: 05 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Cindy Tahl, as Attorney-in-Fact

Key filing fact

Matt Abernethy filed Form 4 for FATE THERAPEUTICS INC (FATE) on 15 Jun 2026.

Key facts

This page summarizes Matt Abernethy's Form 4 filing for FATE THERAPEUTICS INC (FATE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 16:07.

Change

Previous filing in this sequence was filed on 05 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001724097 Primary reporting owner

ABERNETHY MATT

Relationship: Director
Address: C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO
Signature: /s/ Cindy Tahl, as Attorney-in-Fact
Signature date: 15 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FATE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +87,900
Change %
Price: $0.000000^*
Shares after: 87,900
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 87,900
Exercise price: $2.06
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.

Footnote F2

The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.